ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

10054	Companies
205286	Keywords
135520	Articles
108835	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 5 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024
BRIEF

published on 09/25/2024 at 22:06, 1 year 5 months ago

Abivax Announces Ulcerative Colitis Combination Therapy Strategy and Preclinical Data

Obefazimod Ulcerative Colitis Preclinical Data Combination Therapy Etrasimod
PRESS RELEASE

published on 09/25/2024 at 22:01, 1 year 5 months ago

Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
Abivax announces preclinical data of Obefazimod and Etrasimod combination therapy in IBD mouse model, aiming to break through efficacy ceiling in UC treatment. More updates expected in Q4 2024

Abivax Obefazimod Preclinical Data Etrasimod IBD Mouse Model
BRIEF

published on 09/19/2024 at 18:05, 1 year 5 months ago

ABIVAX: Number of shares and voting rights as of August 31, 2024

Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF

published on 09/09/2024 at 23:01, 1 year 6 months ago

Statement by Marc de Garidel on Abivax's 2024 Half-Year Financial Report

Financial Report Abivax Transparency IFRS Heritage
BRIEF

published on 09/09/2024 at 22:40, 1 year 6 months ago

ABIVAX presents its 2024 half-year results

Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF

published on 09/09/2024 at 22:06, 1 year 6 months ago

Abivax financial results for the first half of 2024

Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE

published on 09/09/2024 at 22:01, 1 year 6 months ago

Abivax presents first-half 2024 financial results
Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases

Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF

published on 08/29/2024 at 18:05, 1 year 6 months ago

ABIVAX: Status of shares and voting rights as of July 31, 2024

Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF

published on 08/06/2024 at 08:35, 1 year 7 months ago

Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial

Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test

Accesswire

Published on 03/19/2026 at 13:30, 14 minutes ago

Hillcrest Energy Technologies CEO Don Currie Discusses ZVS Technology and Commercialization Progress in Stocks To Watch Investor Interview
Published on 03/19/2026 at 13:30, 14 minutes ago

ACCESS Newswire Reports Fourth Quarter and Full Year 2025 Results
Published on 03/19/2026 at 13:15, 29 minutes ago

Worksport Presents New Premium "Game Changer" Tonneau Cover Model to Industry Buyers at Keystone BIG Show; Initiates Pre-Orders Ahead of Near-Term Commercial Launch
Published on 03/19/2026 at 13:10, 34 minutes ago

Adcore to Publish Fourth Quarter and 2025 Year End Results on March 26th, 2026
Published on 03/19/2026 at 13:00, 44 minutes ago

Dateline Secures Second Rig to Fast-Track Colosseum REE Program

View all ACCESSWIRE

EQS Group

Published on 03/19/2026 at 13:38, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 03/19/2026 at 13:10, 33 minutes ago

DCK Showcases Expanded Professional Power Tool and Outdoor Power Equipment Portfolio at EISENWARENMESSE 2026, Strengthening European Market Commitment
Published on 03/19/2026 at 13:00, 43 minutes ago

Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard
Published on 03/19/2026 at 12:56, 47 minutes ago

ABB Ltd: ABB shareholders approve all proposals at 2026 annual general meeting
Published on 03/19/2026 at 12:10, 1 hour 33 minutes ago

ZPMC Completes First Emissions Rights Transaction in Shanghai

Les Echos

Published on 03/19/2026 at 08:45, 4 hours 59 minutes ago

Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 6 hours 44 minutes ago

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 6 hours 44 minutes ago

2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 18 hours 2 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 19 hours 44 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results

View all LES ECHOS COMFI WIRE